The Triple Marker Test is a prenatal blood screening test performed during the second trimester of pregnancy, usually between 15 and 20 weeks. It measures the levels of three substances in the mother’s blood:

1. Alpha-fetoprotein (AFP)
2. Human chorionic gonadotropin (hCG)
3. Unconjugated estriol (uE3)

The test helps assess the risk (not a diagnosis) of certain fetal conditions, such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and neural tube defects like spina bifida. Results are interpreted along with factors such as the mother’s age, weight, gestational age, and medical history.